Novartis CEO sees no need for big takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Bristol-Myers Squibb (BMY) Granted European Commission Approval Opdivo (Nivolumab)
June 2, 2017 5:06 PM UTCBristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Todays decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for... More
Bristol-Myers Squibb (BMY) & Seattle Genetics (SGEN) Announce Expanded Collaboration to Evaluate Combination of Opdivo (Nivolumab) & ADCETRIS (Brentuximab Vedotin) in Phase 3 Clinical Trial
June 2, 2017 6:03 AM UTCBristol-Myers Squibb Company (NYSE: BMY) and Seattle Genetics, Inc. (Nasdaq:... More
